We investigated the effect of atezolizumab plus bevacizumab on the frequencies of CD4+ T-cell phenotypes in 28 patients with HCC, comparing baseline and week 3 in 13 PR +SD and 15 PD patients (Figure 2a). The gene discussed is CD4; the disease is hepatocellular carcinoma.